erlotinib hydrochloride has been researched along with lapatinib ditosylate in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (lapatinib ditosylate) | Trials (lapatinib ditosylate) | Recent Studies (post-2010) (lapatinib ditosylate) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 7 | 0 | 4 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | lapatinib ditosylate (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0302 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0242 | |
| Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | 0.0163 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, L; Feng, J; Hu, B; Huang, L; Tang, PC; Xu, Z; Zhang, L; Zhang, X | 1 |
1 other study(ies) available for erlotinib hydrochloride and lapatinib ditosylate
| Article | Year |
|---|---|
Synthesis and biological evaluation of pyrrolopyridazine derivatives as novel HER-2 tyrosine kinase inhibitors.
Topics: Drug Design; Enzyme Inhibitors; Models, Molecular; Pyridazines; Pyrroles; Structure-Activity Relationship; TYK2 Kinase | 2009 |